Merck Uses Phosphoproteomics to Identify Potential Biomarkers for Cancer Drug Development

In a study, Merck scientists identified 71 phosphoproteins that could be useful biomarkers for predicting the efficacy of drugs targeting a cancer-linked signaling pathway.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.